Bio-Rad Laboratories, Inc. Class A Common Stock vs Devon Energy Corp — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $358.09 (market cap $9.43B), while Devon Energy Corp trades at $44.97 (market cap $49.94B). The key difference: Devon Energy Corp is far larger — about 5.3× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Devon Energy Corp pays a 2.82% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | DVN | |
|---|---|---|
Market Cap | $9.43B | $49.94B |
Sector | Health | Energy |
52-Week High | $356.25 | $52.07 |
52-Week Low | $241.71 | $31.74 |
Enterprise Value | $9.18B | $60.68B |
Dividend Yield | — | 2.82% |
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $351.10, down 0.97% on the day but maintaining strength near its 52-week high. The stock shows bullish technical momentum with strong moving average support and recently beat Q2 2026 earnings estimates with $2.62 EPS versus $1.75 expected. Fundamentals show improving profitability with 29.41% net margin in 2025, though revenue remains flat at $2.6 billion. Analyst consensus remains positive with 7 buy ratings and $350 price target.
BIO presents a mixed outlook with strong technical momentum and improving profitability offset by flat revenue growth and elevated valuation multiples. The stock's current price aligns with analyst consensus target, suggesting limited near-term upside. Key risks include academic research market softness and competitive pressures in life science instruments. Institutional ownership trends show continued confidence with recent position increases by major funds.
Devon Energy (DVN) trades at $44.93, down 0.95% on the day, amid a bullish technical signal and strong Q2 2026 earnings that beat estimates. The company reported EPS of $1.57 versus $1.40 expected, driven by merger synergies and higher oil production. Valuation ratios remain attractive with a P/E of 9.87 and EV/EBITDA of 6.89. Recent news highlights a 33% dividend hike and accelerated debt reduction, reinforcing positive sentiment.
The outlook for DVN is positive, supported by robust free cash flow, shareholder returns, and operational execution. Key opportunities include synergy realization from the Coterra merger and a consensus price target of $61.91. Risks involve oil price volatility and integration challenges. Wall Street sentiment is strongly bullish with 71% buy ratings.
Trailing returns across standard periods
Latest headlines on both assets
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →